175 related articles for article (PubMed ID: 11133779)
1. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
[TBL] [Abstract][Full Text] [Related]
2. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
3. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
Arthur JR; Lee JP; Snyder EY; Seyfried TN
Neurochem Res; 2012 Jun; 37(6):1335-43. PubMed ID: 22367451
[TBL] [Abstract][Full Text] [Related]
5. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
6. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
7. Substrate reduction therapy for glycosphingolipid storage disorders.
Lachmann RH; Platt FM
Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
Elliot-Smith E; Speak AO; Lloyd-Evans E; Smith DA; van der Spoel AC; Jeyakumar M; Butters TD; Dwek RA; d'Azzo A; Platt FM
Mol Genet Metab; 2008 Jun; 94(2):204-11. PubMed ID: 18387328
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
Pelled D; Lloyd-Evans E; Riebeling C; Jeyakumar M; Platt FM; Futerman AH
J Biol Chem; 2003 Aug; 278(32):29496-501. PubMed ID: 12756243
[TBL] [Abstract][Full Text] [Related]
10. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease.
Lee JP; Jeyakumar M; Gonzalez R; Takahashi H; Lee PJ; Baek RC; Clark D; Rose H; Fu G; Clarke J; McKercher S; Meerloo J; Muller FJ; Park KI; Butters TD; Dwek RA; Schwartz P; Tong G; Wenger D; Lipton SA; Seyfried TN; Platt FM; Snyder EY
Nat Med; 2007 Apr; 13(4):439-47. PubMed ID: 17351625
[TBL] [Abstract][Full Text] [Related]
11. Deletion of tumor necrosis factor-α ameliorates neurodegeneration in Sandhoff disease mice.
Abo-Ouf H; Hooper AW; White EJ; Janse van Rensburg HJ; Trigatti BL; Igdoura SA
Hum Mol Genet; 2013 Oct; 22(19):3960-75. PubMed ID: 23727835
[TBL] [Abstract][Full Text] [Related]
12. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
[TBL] [Abstract][Full Text] [Related]
13. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.
Yamaguchi A; Katsuyama K; Suzuki K; Kosaka K; Aoki I; Yamanaka S
J Mol Med (Berl); 2003 Mar; 81(3):185-93. PubMed ID: 12682727
[TBL] [Abstract][Full Text] [Related]
14. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
Jeyakumar M; Butters TD; Dwek RA; Platt FM
Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice.
Norflus F; Tifft CJ; McDonald MP; Goldstein G; Crawley JN; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
J Clin Invest; 1998 May; 101(9):1881-8. PubMed ID: 9576752
[TBL] [Abstract][Full Text] [Related]
16. Substrate deprivation therapy in juvenile Sandhoff disease.
Wortmann SB; Lefeber DJ; Dekomien G; Willemsen MA; Wevers RA; Morava E
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S307-11. PubMed ID: 19898952
[TBL] [Abstract][Full Text] [Related]
17. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.
Wada R; Tifft CJ; Proia RL
Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10954-9. PubMed ID: 11005868
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
Boomkamp SD; Rountree JS; Neville DC; Dwek RA; Fleet GW; Butters TD
Glycoconj J; 2010 Apr; 27(3):297-308. PubMed ID: 20186478
[TBL] [Abstract][Full Text] [Related]
20. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
Ashe KM; Bangari D; Li L; Cabrera-Salazar MA; Bercury SD; Nietupski JB; Cooper CG; Aerts JM; Lee ER; Copeland DP; Cheng SH; Scheule RK; Marshall J
PLoS One; 2011; 6(6):e21758. PubMed ID: 21738789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
